Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

ADTX

Aditxt Inc

Dec 13 • 04:00PM ET

0.3482

Dollar change +0.0053
Percentage change 1.55	%

Healthcare • Biotechnology • USA • NASD

Peers: MRNA BNTX NVAX SAVA INO ALT VXRT AIM PDSB AYTU

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-981.65	Insider Own	0.00%	Shs Outstand	14.23M	Perf Week	-0.26%
Market Cap	5.04M	Forward P/E	-	EPS next Y	-	Insider Trans	-	Shs Float	14.23M	Perf Month	0.09%
Income	-46.25M	PEG	-	EPS next Q	-	Inst Own	0.05%	Short Float	1.27%	Perf Quarter	-98.07%
Sales	0.21M	P/S	23.98	EPS this Y	-	Inst Trans	44.74%	Short Ratio	0.06	Perf Half Y	-99.46%
Book/sh	8.87	P/B	0.04	EPS next Y	-	ROA	-211.16%	Short Interest	0.18M	Perf Year	-99.86%
Cash/sh	0.02	P/C	15.26	EPS next 5Y	-	ROE	-16400.32%	52W Range	0.31 - 338.80	Perf YTD	-99.87%
Dividend Est.	-	P/FCF	-	EPS past 5Y	45.26%	ROI	-871.94%	52W High	-99.90%	Beta	0.98
Dividend TTM	-	Quick Ratio	0.08	Sales past 5Y	151.61%	Gross Margin	-572.37%	52W Low	12.32%	ATR (14)	0.11
Dividend Ex-Date	-	Current Ratio	0.09	EPS Y/Y TTM	88.52%	Oper. Margin	-14220.91%	RSI (14)	20.27	Volatility	6.15% 9.42%
Employees	47	Debt/Eq	2.18	Sales Y/Y TTM	-71.70%	Profit Margin	-21803.99%	Recom	1.00	Target Price	2440.00
Option/Short	No / Yes	LT Debt/Eq	0.13	EPS Q/Q	94.31%	Payout	-	Rel Volume	0.20	Prev Close	0.34
Sales Surprise	120.59%	EPS Surprise	-	Sales Q/Q	-94.49%	Earnings	-	Avg Volume	2.86M	Price	0.35
SMA20	-0.30%	SMA50	-45.16%	SMA200	-99.36%	Trades		Volume	581,687	Change	1.55%

Dec-12-24 08:15AM	Aditxt's Subsidiary Adimune Successfully Completes Preclinical Efficacy and Safety Studies for Its Immune Modulation Therapeutic ADI Platform, Advancing Toward First-in-Human Clinical Trials (Business Wire)
Nov-19-24 07:17AM	Appili Therapeutics Announces Receipt of Final Court Order for Arrangement with Aditxt, Inc. (GlobeNewswire)
Nov-14-24 04:36PM	Evofem Biosciences Announces Financial Results for the Third Quarter of 2024 (PR Newswire) -7.32%
07:15AM	Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2025 (GlobeNewswire)
Nov-08-24 08:30AM	Aditxt Provides Update on Equity Line of Credit, ATM Usage, and Outstanding Number of Shares (Business Wire)
08:30AM	Loading…
Nov-07-24 08:30AM	Aditxt's Target Acquisition Appili Therapeutics Announces Results of Special Meeting of Shareholders (Business Wire) -22.11%
Nov-06-24 05:55PM	Appili Therapeutics Announces Results of Special Meeting of Shareholders (GlobeNewswire)
08:30AM	Aditxt Acquisition Target Evofem Biosciences Secures Investor Support Through Voting Agreements for Merger with Aditxt's Subsidiary Adifem (Business Wire)
08:00AM	Evofem Secures Investor Support for Proposed Merger through Voting Agreements (PR Newswire)
Oct-31-24 08:30AM	Aditxts Target Acquisition Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission (Business Wire)
07:15AM	Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission (GlobeNewswire)
Oct-30-24 05:00PM	Aditxt To Host Virtual Stakeholder Update and Q&A Session on Friday, November 1, 2024, at 11:30 AM Eastern Time (Business Wire) -5.84%
Oct-29-24 08:15AM	Sylvia Hermina Joins Aditxt's Board of Directors, Elevating Leadership with Broader Perspectives (Business Wire) -18.07%
Oct-28-24 08:15AM	Aditxt Completes Final Equity Investment and Key Milestone Under the Amended and Restated Merger Agreement with Evofem (Business Wire) -14.72%
Oct-21-24 08:15AM	Aditxt to Host a Virtual Fireside Chat with Aditxt CEO Amro Albanna and Evofem CEO Saundra Pelletier, Moderated by MD & Media Personality Dr. Drew Pinsky, on October 28, 2024, at 11:30 AM Eastern Time (Business Wire)
05:28PM	Loading…
Oct-12-24 05:28PM	Aditxt CEO Clarifies NASDAQ Compliance and Capital Strategy (TipRanks)
Oct-10-24 08:15AM	Aditxts Acquisition Target Appili Therapeutics Will Hold a Special Meeting of Shareholders on November 6, 2024, to Vote on the Transaction and Secure Appilis Shareholder Approval (Business Wire)
Oct-09-24 10:52AM	Aditxt To Host Stakeholder Update and Q&A Session on Friday, October 11, 2024, at 11:30 AM Eastern Daylight Time (Business Wire) -14.18%
Oct-08-24 08:15AM	Aditxt Completes Third Parent Equity Investment Under Amended and Restated Merger Agreement With Evofem (Business Wire) -5.37%
Oct-03-24 08:15AM	Aditxt Delivers Shareholder Update and 2024 Year-End Plan (Business Wire) -28.15%
Sep-27-24 08:15AM	Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-40 Reverse Stock Split Effective at the Open of Trading on October 2, 2024 (Business Wire) -25.60%
Sep-24-24 08:15AM	Evofem Biosciences Files Preliminary Proxy for Stockholder Approval of the Acquisition by Aditxt (Business Wire) -15.87%
Sep-20-24 08:15AM	Aditxt's Subsidiary Pearsanta to Collaborate with Evofem Biosciences for Targeted U.S. Launch of Endometriosis Diagnostic in Mid-2025 (Business Wire)
Sep-09-24 08:15AM	Aditxt and Evofem Sign Second Amendment to Amended and Restated Merger Agreement, Target Closing of Acquisition in Fourth Quarter of 2024 (Business Wire)
Sep-04-24 08:15AM	Aditxt Subsidiary Pearsanta Submits a Grant Application Seeking to Advance Clinical Trials for Mitomic Prostate Test, Targeting Early Detection in High-Risk Patients (Business Wire) -19.68%
Aug-29-24 08:15AM	Aditxt to Present at the H.C. Wainwright 26th Annual Global Investment Conference September 9th-11th, 2024 (Business Wire) -7.64%
Aug-26-24 08:15AM	Aditxts Precision Health Subsidiary, Pearsanta, Appoints Christopher Mitton as President as it Seeks to Complete Clinical Validation Studies for its Mitomic Endometriosis Test (MET) and Mitomic Prostate Test (MPT) (Business Wire) -11.70%
Aug-21-24 08:15AM	Aditxt Announces Third Amendment to Arrangement Agreement with Appili Therapeutics (Business Wire)
Aug-20-24 08:17AM	Evofem Biosciences Addresses the Impact of GLP-1 Medications on Oral Contraceptive Absorption and Introduces Phexxi as a Non-Oral Solution (PR Newswire) -16.67%
Aug-14-24 07:00AM	Evofem Biosciences Announces Financial Results for the Second Quarter of 2024 (PR Newswire)
08:15AM	Loading…
Aug-13-24 08:15AM	Aditxt Announces the Successful Passage of all Proposals at Recent Annual Shareholders' Meeting, Setting the Stage for 2024 and 2025 Strategic Plans (Business Wire)
Aug-12-24 07:30AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace) -11.38%
Aug-09-24 04:15PM	Aditxt Announces Closing of $1.2 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules (Business Wire)
08:00AM	Aditxt Announces $1.2 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules (Business Wire)
Aug-07-24 08:15AM	Aditxt Subsidiary Pearsanta Seeks Clinical Trial Translational Endpoints Research Award for Early Detection of Ovarian Cancer (Business Wire) +29.39%
Jul-25-24 09:00AM	Evofem Biosciences to Present at the OTCQB Venture Virtual Investor Conference on August 1st (GlobeNewswire)
08:30AM	Aditxt Signs Second Amendment to the Arrangement Agreement with Appili Therapeutics, Targeting September 30 Closing of the Acquisition (Business Wire)
Jul-23-24 08:47AM	Evofem Signs Phexxi License Agreement for Middle East with Pharma 1 (PR Newswire) +5.71%
Jul-17-24 06:30AM	Aditxt and Evofem Amend and Restate Merger Agreement, Targeting September 30 Closing (Business Wire) +45.01%
Jul-15-24 07:20AM	Lupin Divests U.S. Commercial Women's Health Specialty Business to Evofem, including SOLOSEC (PR Newswire) -6.21%
Jun-27-24 08:36AM	Hello Alpha Partners with Evofem to Offer Phexxi as a Hormone-Free Contraception Solution on its Platform for Women's Healthcare (PR Newswire)
Jun-11-24 08:36AM	Evofem Announces Issuance of New U.S. Patent Covering Phexxi Composition of Matter (PR Newswire)
May-20-24 10:53PM	ADTX Stock Earnings: Aditxt Reported Results for Q1 2024 (InvestorPlace)
May-15-24 06:50AM	Evofem Biosciences Announces Financial Results for the First Quarter of 2024 (PR Newswire) -6.82%
May-03-24 02:14PM	CORRECTING and REPLACING Aditxt Announces Pricing of $4.2 Million Private Placement Priced At-The-Market under Nasdaq Rules (Business Wire) -6.88%
09:00AM	Aditxt Announces Pricing of $4.2 Million Private Placement Priced At-The-Market under Nasdaq Rules (Business Wire)
Apr-02-24 08:30AM	Aditxt Signs a Definitive Agreement to Acquire Appili Therapeutics Inc., Developer of a Biodefense Vaccine Funded by the U.S. Department of Defense (DoD) (Business Wire) +5.97%
07:30AM	Appili Therapeutics Signs Definitive Agreement to be Acquired by Aditxt, Inc. (GlobeNewswire)
Mar-27-24 08:36AM	Evofem Reports $18.2 million of Phexxi Net Product Sales in 2023 (PR Newswire)
Mar-20-24 08:54AM	Evofem Negotiates Improved Rebate for Hormone-Free 'In the Moment' Contraceptive PHEXXI with Medi-Cal (PR Newswire) +5.25%
Mar-07-24 07:54AM	For Women Using GLP-1 Receptor Agonists who take Oral Birth Control Pills, Hormone-Free Phexxi Contraceptive Gel is a Logical Solution to Help Prevent Unintended Pregnancy (PR Newswire) +13.51%
Feb-01-24 08:00AM	Evofem Biosciences Announces Strong Preliminary Results, Record Phexxi Net Sales for Fiscal 2023 (PR Newswire)
Jan-30-24 08:30AM	Aditxt, Inc. Acquires Proprietary Electroencephalography (EEG) Brain Monitoring Technologies and Devices, Including NeuroCap and NeuroEEG for Telehealth and Tele-neurology Applications (Business Wire)
Jan-08-24 08:30AM	Aditxt, Inc.s Subsidiary Pearsanta, Inc. Acquires MDNA Life Sciences Inc.s Proprietary Mitomic Testing Platform Pioneering Early Disease and Cancer Detection in a Transaction Valued at Approximately $25 Million (Business Wire)
Jan-05-24 08:30AM	Aditxt Announces Closing of $6.0 Million Private Placement Priced At-The-Market under Nasdaq Rules (Business Wire)
Jan-02-24 08:30AM	Aditxt, Inc. Regains Compliance with Nasdaq Stockholders Equity Requirement (Business Wire) -27.60%
Dec-29-23 05:07PM	Aditxt Announces $6 Million Private Placement Priced At-The-Market under Nasdaq Rules (Business Wire) +37.55%
Dec-12-23 11:20AM	Why Is Aditxt (ADTX) Stock Up 58% Today? (InvestorPlace) +60.26%
08:30AM	Aditxt, Inc. Enters into Definitive Agreement to Acquire Evofem Biosciences, Inc., Creator of Phexxi, the First and Only FDA-Approved Hormone-Free Contraceptive Gel, to Address Diverse Reproductive Health Needs of Women Globally (Business Wire)
Nov-30-23 07:39AM	Why Is Aditxt (ADTX) Stock Up 70% Today? (InvestorPlace) +13.43%
Oct-06-23 08:00AM	Aditxt, Inc. to Present at 8th Annual Dawson James Conference (GlobeNewswire)
Oct-05-23 08:00AM	Aditxt, Inc. Announces Appointment of Ernie Lee as CEO of its Wholly-Owned Subsidiary, Pearsanta, to Lead Launch of Test2Treat.me Platform (Business Wire)
Sep-21-23 09:35AM	Dawson James Securities Announces October Date for 8th Annual Small Cap Growth Conference (GlobeNewswire)
Sep-08-23 07:05AM	Aditxt, Inc. (NASDAQ: ADTX) Announces Participation at the H.C. Wainwright 25th Annual Global Investment Conference September 11th-13th, 2023 (Business Wire)
Sep-06-23 04:30PM	Aditxt Announces Closing of $10.0 Million Private Placement Priced At-The-Market under Nasdaq Rules (Business Wire) -10.46% -10.68%
Aug-31-23 07:00PM	Aditxt Announces $10.0 Million Private Placement Priced At-The-Market under Nasdaq Rules (Business Wire) +461.22% -24.80%
Aug-18-23 07:02AM	Aditxt, Inc. (NASDAQ: ADTX) Provides Shareholder Update and Planned Strategy for Achieving Commercial Scale (Business Wire) +5.76%
Aug-17-23 04:12PM	CORRECTING and REPLACING Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-40 Reverse Stock Split Effective at the Open of Trading on August 18, 2023 (Business Wire) +31.50%
Jun-20-23 07:49AM	Aditxt, Inc.s Wholly-Owned Subsidiary Pearsanta, Inc. Looks to Expand Customer Base, Payor Access, and Genetic Testing with a Non-Binding Letter of Intent to Acquire Natural State Laboratories and Natural State Genomics (Business Wire)
May-19-23 06:10AM	Aditxt First Quarter 2023 Earnings: US$1.31 loss per share (vs US$6.80 loss in 1Q 2022) (Simply Wall St.)
May-05-23 07:05AM	Aditxt Subsidiary Adimune Signs Clinical Trial Agreement with Top Research Institution to Study Stiff Person Syndrome (Business Wire)
Apr-24-23 04:15PM	Aditxt Announces Closing of $1.9 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules (Business Wire) -8.51%
Apr-20-23 01:35PM	Aditxt Announces $1.9 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules (Business Wire) +17.44%
08:00AM	Aditxt Signs Asset Purchase Agreement to Acquire Fifty Percent Ownership of Global Response Aid with Rights to Manufacture and Market Broad-Spectrum Antiviral Drug Avigan (Business Wire)
Apr-17-23 07:00AM	Aditxt Issues Shareholder Update (Business Wire)
Mar-08-23 08:30AM	Aditxt Names Media Industry Veteran Maureen Connolly as Chief Content and Engagement Officer (Business Wire)
Mar-03-23 08:30AM	Aditxt Retains Riverside Management Group as Advisor to Support Strategic M&A Driven Acquisitions by Subsidiary Pearsanta, Inc. (Business Wire)
Feb-14-23 08:30AM	Aditxt Forms its Second Subsidiary, Pearsanta, Inc., to Accelerate the Growth of its AditxtScore Program and Appoints Healthcare Executive and Current Head of AditxtScore Anthony Voorhies to Serve as its President (Business Wire) +7.80%
Jan-12-23 08:46AM	Is the Options Market Predicting a Spike in Aditx (ADTX) Stock? (Zacks)
Jan-03-23 09:00AM	Aditxt Forms Adimune, Inc. as a Wholly Owned Subsidiary with a Focus on Immune Modulation Therapies and Appoints Dr. Friedrich Kapp, Former President of the Therapeutic Business Unit at Schering AG, as its Chairman and CEO (Business Wire) +36.84%
Dec-05-22 08:52AM	Implied Volatility Surging for Aditx Therapeutics (ADTX) Stock Options (Zacks)
Oct-21-22 09:00AM	Aditxts (Nasdaq: ADTX) Adimune Program Has Initiated the Manufacturing Process of Immunotherapeutic Drug Candidate, ADI-100 in Preparation for Planned Psoriasis First-in-Human Trials (Business Wire)
Oct-12-22 09:00AM	Aditxt, Inc. (Nasdaq: ADTX) Announces Development and Publication of a Mathematical Model for Predicting Longevity and Variations of Immune Response to Immunization to SARS-CoV-2 Infection (Business Wire)
Oct-07-22 09:00AM	FedEx Features AditxtScore Immune Monitoring Center and its Service in Richmond, VA, Highlighting the Importance of Quantifying Immune Health (Business Wire) +9.97%
Sep-30-22 08:34AM	Is the Options Market Predicting a Spike in Aditx (ADTX) Stock? (Zacks)
Sep-29-22 09:00AM	Aditxt, Inc. (NASDAQ: ADTX) Announces That it Has Regained Compliance with Nasdaq Listing Requirements (Business Wire) +10.46%
Sep-27-22 09:00AM	Aditxt Inc. (Nasdaq: ADTX) Provides Corporate Highlights Post Reverse Stock Split and Closing of $20M Public Offering (Business Wire) +6.56%
Sep-20-22 04:09PM	Aditxt Announces Closing of $20.0 Million Public Offering (Business Wire) -14.08%
Sep-16-22 09:20AM	Aditxt Announces Pricing of $20.0 Million Public Offering (Business Wire) -58.52%
Sep-13-22 04:15PM	Aditxt, Inc. (Nasdaq: ADTX) Announces 1-for-50 Reverse Stock Split Effective Pre-Market Opening on September 14, 2022 (Business Wire) +113.75% -38.22%
Aug-02-22 08:17AM	IBN (InvestorBrandNetwork) Announces Latest Episode of The Bell2Bell Podcast featuring Amro Albanna, CEO of Aditxt, Inc. (GlobeNewswire)
Jul-08-22 08:30AM	Aditxt, Inc. Successfully Completes Preclinical Toxicity Study of Its Psoriasis Drug Candidate ADI-100 Advancing it Closer to First-in-Human Trials (Business Wire) +50.00%
Jun-14-22 02:00PM	Premier Medical Laboratory Services Now Offering AditxtScore Personalized Immune Test for COVID-19 (PR Newswire) +23.21%
Apr-14-22 09:00AM	Aditxt, Inc. Partners with Guthy-Renker Affiliate GRS to Launch Consumer Awareness Campaign for AditxtScore to Accelerate Adoption and Revenue Growth (Business Wire)
Apr-05-22 08:30AM	Aditxt Signs Revenue-Sharing Agreement with Cellvera for up to $30M, and Hosts a Live Business Update Webinar on April 14th (Business Wire)
Mar-23-22 08:30AM	Aditxt to Participate in the 2022 Virtual Growth Conference (Business Wire) +14.62%
Jan-18-22 08:30AM	Aditxt Submits Two Requests for Emergency Use Authorization to FDA for AditxtScore for COVID-19 Tests Which Measure the Quantity and Quality of Antibodies Against COVID-19 and its Variants Including Omicron (Business Wire)
Jan-14-22 09:00AM	Aditxt, Inc. to Participate in Edison Groups Global Healthcare "Open House" Virtual Conference From January 25th-27th, 2022 (Business Wire)
Jan-12-22 09:00AM	Aditxt Provides Online Business Update Townhall Meeting with Amro Albanna, Co-Founder & CEO (Business Wire)
Dec-31-21 06:00PM	Lifshitz Law Firm, P.C. Announces Investigation of Aditxt, Inc. (ADTX) (ACCESSWIRE) +7.85%

Aditxt, Inc. is a biotech innovation company, which engages in the development and commercialization of technologies focusing on monitoring and modulating the immune system. Its innovation portfolio includes Adimune and AditxtScore. The company was founded by Leonard L. Bailey, Shahrokh Shabahang, and Amro Albanna on September 28, 2017 and is headquartered in Richmond, VA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
HRT FINANCIAL LP	10% Owner	Oct 15 '24	Buy	1.50	15,636	23,454	25,434	Oct 17 01:58 PM
HRT FINANCIAL LP	10% Owner	Oct 16 '24	Sale	1.17	25,534	29,875	0	Oct 17 01:58 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ADTX

Aditxt Inc

Upgrade your FINVIZ experience